부신피질암(ACC) 치료 시장 규모 : 치료 유형별, 최종 사용자별, 유통 채널별, 지역별 예측

Adrenocortical Carcinoma Treatment Market Size And Forecast

Adrenocortical Carcinoma Treatment Market size was valued at USD 720.5 Million in 2024 and is projected to reach USD 832.18 Million by 2032, growing at a CAGR of 2.81% during the forecast period 2026 to 2032.

The Adrenocortical Carcinoma (ACC) Treatment Market is a specialized segment of the oncology industry focused on the medical interventions, pharmaceutical therapies, and surgical procedures designed to manage a rare and aggressive malignancy originating in the adrenal cortex. This market encompasses the entire lifecycle of patient care, from diagnostic imaging and surgical resection to the administration of systemic therapies such as chemotherapy and hormonal agents. Because ACC is characterized by both high recurrence rates and complex endocrine dysfunction, the market definition includes products and services that aim to suppress tumor growth while simultaneously managing hormone overproduction.

From a therapeutic perspective, the market is primarily defined by its reliance on multimodal treatment protocols. This includes surgical interventions, such as adrenalectomy, which remains the first line treatment for localized disease, and pharmacological segments dominated by mitotane an orphan drug that remains the standard of care due to its unique ability to target adrenocortical cells. The market scope also covers cytotoxic chemotherapy combinations (notably the EDP M regimen) and a growing pipeline of targeted therapies and immunotherapies, such as PD 1/PD L1 inhibitors, which are being explored to address significant unmet medical needs in metastatic cases.

The market structure is categorized by disease stage, treatment modality, and end user settings. It is segmented into localized, locally advanced, and metastatic disease stages, each requiring distinct economic and clinical resources. End users typically include high volume specialty oncology centers and research hospitals, where multidisciplinary teams of surgeons, endocrinologists, and oncologists provide coordinated care. Additionally, the market definition extends to include diagnostic infrastructure, such as advanced PET CT imaging and molecular biomarker testing, which are essential for early detection and personalized treatment planning.

In terms of economic dynamics, the market is largely driven by its classification as an ultra orphan disease sector, where low patient volumes are offset by high treatment complexity and regulatory incentives for drug development. Strategic growth in this space is currently fueled by advancements in precision medicine and genomic profiling, as well as an increasing global focus on rare cancer research. While historically concentrated in North America and Europe due to established healthcare infrastructures, the market is expanding globally as diagnostic sensitivity improves and emerging economies invest in specialized cancer care facilities.

Global Adrenocortical Carcinoma Treatment Market Drivers

The global Adrenocortical Carcinoma (ACC) treatment market is undergoing a significant transformation. As of 2026, the market is valued at approximately $2.45 billion and is projected to experience steady growth driven by a shift toward precision medicine and improved patient identification.

Rising Incidence and Improved Diagnosis: Although Adrenocortical Carcinoma remains an ultra rare malignancy with a worldwide incidence of approximately 0.5 to 2.0 cases per million the documented patient pool is expanding. This growth is not necessarily due to a biological surge in the disease, but rather a sharp increase in "incidentalomas." As routine medical imaging for unrelated conditions becomes more common, physicians are identifying adrenal masses at much higher rates. Furthermore, increased clinical awareness among endocrinologists ensures that these cases are accurately triaged and diagnosed as ACC rather than benign adenomas, effectively broadening the addressable market for specialized therapies like Mitotane and newer systemic agents.

Advancements in Diagnostic Technologies: The integration of high resolution imaging and molecular diagnostics has revolutionized the early detection of ACC. Modern MRI and CT protocols now utilize artificial intelligence (AI) to differentiate between benign and malignant adrenal tissues with unprecedented precision. Beyond traditional imaging, the rise of Liquid Biopsies and Next Generation Sequencing (NGS) allows for the detection of circulating tumor DNA (ctDNA) and specific genetic markers. These technologies enable clinicians to identify the disease at earlier, more treatable stages, which significantly boosts the adoption of aggressive early intervention therapies.

Growth in Research & Development: Investment in oncology R&D has reached new heights in 2026, with a particular focus on rare and aggressive "orphan" cancers. Pharmaceutical giants and biotech startups are aggressively pursuing clinical trials to move beyond the traditional "EDP M" (etoposide, doxorubicin, cisplatin, and mitotane) regimen. Current research is heavily focused on multi center international collaborations, which solve the historical challenge of small patient populations. These trials are essential for validating the efficacy of novel compounds, thereby creating a robust pipeline of evidence based treatments that fuel market confidence.

Emergence of Targeted Therapy: The treatment landscape is pivoting from broad spectrum chemotherapy to precision oncology. Targeted therapies focusing on the IGF 1R pathway and Wnt/B catenin signaling which are frequently altered in ACC are showing promise in clinical settings. Simultaneously, the emergence of Immune Checkpoint Inhibitors (such as PD 1/PD L1 inhibitors) is offering a lifeline to patients with metastatic or recurrent disease. By leveraging the body's own immune system, these therapies provide a more tolerable and effective alternative to cytotoxic drugs, representing the fastest growing segment of the ACC market.

High Unmet Medical Need: Despite recent progress, the prognosis for advanced stage ACC remains challenging, with 5 year survival rates often hovering below 15%. This stark reality creates a massive "pull" factor in the market, where there is urgent demand for salvage therapies and second line treatments. Because current standard of care options are limited and often associated with high toxicity, regulatory bodies are more likely to grant accelerated approvals for innovative drugs. This high unmet need ensures that any breakthrough therapy will see rapid market penetration and high value based pricing.

Orphan Drug Incentives: Regulatory frameworks like the U.S. Orphan Drug Act and similar EU initiatives are critical catalysts for market growth. These programs offer developers substantial benefits, including a 25% clinical testing tax credit, waivers for multi million dollar filing fees, and up to seven years of market exclusivity. These financial and regulatory "de risking" measures make it economically viable for companies to invest in a niche market like ACC, where the small patient population might otherwise discourage the high costs of drug development.

Global Adrenocortical Carcinoma Treatment Market Restraints

While the market for Adrenocortical Carcinoma (ACC) treatment is advancing, several formidable barriers continue to impede its full growth potential. As of 2026, these restraints range from economic hurdles to the biological complexities of the disease itself.

High Cost of Treatment: The financial burden of managing Adrenocortical Carcinoma is a major barrier to global market expansion. Advanced therapeutic regimens, including immunotherapy and targeted molecular agents, can cost patients upwards of $150,000 annually. When combined with the high costs of specialized surgical resection, long term Mitotane therapy, and frequent high resolution imaging (CT/MRI), the cumulative expense often exceeds the coverage limits of standard insurance. This economic strain is particularly acute in low and middle income regions, where the lack of specialized reimbursement frameworks for orphan diseases effectively denies a significant portion of the global population access to life saving innovations.

Rarity of the Disease (Small Patient Pool): ACC is classified as an "ultra orphan" disease, affecting only 1 to 2 individuals per million each year. This scarcity presents a fundamental commercial challenge: the small patient pool offers limited return on investment (ROI) for pharmaceutical companies, often discouraging the massive capital injection required for drug development. Furthermore, the limited number of eligible patients makes it exceedingly difficult to recruit sufficient participants for statistically significant Phase III clinical trials. This "recruitment bottleneck" results in longer development timelines and a persistent lack of high quality clinical data compared to more common cancers like breast or lung.

Limited Treatment Options: The therapeutic arsenal for ACC remains remarkably narrow. For decades, the market has relied heavily on a single primary drug, Mitotane, which often serves as the backbone of treatment despite its complex administration and narrow therapeutic window. While combination chemotherapy (the EDP regimen) is used for advanced cases, there is a notable absence of diverse systemic therapies. This lack of competition and variety in the treatment pipeline restricts market growth and leaves patients with few alternatives when first line therapies fail, leading to a stagnant competitive landscape.

Late Diagnosis and Diagnostic Challenges: One of the most significant clinical restraints is the high rate of late stage diagnosis. Due to the non specific nature of ACC symptoms such as back pain, abdominal fullness, or weight changes the disease is frequently misdiagnosed as benign adrenal masses or other less severe conditions. By the time many patients receive an accurate diagnosis, the cancer has often reached Stage III or IV, where curative surgery is no longer an option. This diagnostic lag reduces the overall demand for curative intent therapies and shifts the market toward palliative care, which typically involves lower cost, lower volume drug utilization.

Drug Resistance and Poor Treatment Outcomes: Adrenocortical Carcinoma is notoriously resistant to conventional cytotoxic chemotherapy. The high expression of the MDR1 (multi drug resistance) gene in adrenal tissue allows tumor cells to effectively "pump out" therapeutic agents before they can work. This inherent biological resistance leads to high recurrence rates often exceeding 50% post surgery and diminishes the perceived value of existing pharmaceutical interventions. The struggle to achieve consistent, long term clinical outcomes remains a major deterrent for healthcare providers and payers, limiting the broader adoption of current systemic drugs.

Side Effects and Toxicity: The "gold standard" drug for ACC, Mitotane, is associated with a severe side effect profile, including significant gastrointestinal distress, neurological impairment, and adrenal insufficiency. Patients often require complex hormone replacement therapy to manage these drug induced imbalances. These toxicities frequently lead to treatment discontinuation or dose reductions that compromise efficacy. The high "dropout" rate due to poor tolerability creates a volatile market environment where therapy adherence is low, negatively impacting the commercial success of long term maintenance treatments.

Stringent Regulatory and Approval Processes: Navigating the regulatory landscape for rare cancer drugs is a complex and expensive endeavor. Although orphan drug designations provide some incentives, the evidentiary standards required by agencies like the FDA and EMA remain high. Developers must prove "significant benefit" over existing therapies, a difficult task given the lack of a standardized control group in rare disease research. These lengthy and stringent approval pathways increase the "time to market" and escalate the total cost of bringing a new drug to patients, often acting as a barrier for smaller biotech firms with limited capital.

Global Adrenocortical Carcinoma Treatment Market Segmentation Analysis

The Global Adrenocortical Carcinoma Treatment Market is Segmented on the basis of Type Of Treatment, End Users, Distribution Channel, and Geography.

Adrenocortical Carcinoma Treatment Market, By Type Of Treatment

Surgery

Chemotherapy

Radiation Therapy

Targeted Therapies

Based on Type Of Treatment, the Adrenocortical Carcinoma Treatment Market is segmented into Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapies. At VMR, we observe that Surgery currently stands as the dominant subsegment, commanding a substantial market share of approximately 40% to 45% as of 2026. This dominance is fundamentally rooted in its status as the only potentially curative intervention for localized Adrenocortical Carcinoma (ACC). Market drivers for this segment include the rising adoption of minimally invasive techniques, such as laparoscopic and robotic assisted adrenalectomies, which significantly reduce recovery times and post operative complications. North America maintains the highest demand for these advanced surgical procedures due to its robust oncology infrastructure, while the Asia Pacific region is witnessing a rapid surge in adoption rates, fueled by expanding healthcare expenditure in China and India. A critical industry trend influencing this segment is the integration of AI driven surgical planning and high resolution intraoperative imaging, which allows for more precise tumor margin identification.

Following surgery, Chemotherapy represents the second most dominant subsegment, largely driven by the universal clinical reliance on Mitotane the only FDA approved drug specifically for ACC often administered in combination with etoposide, doxorubicin, and cisplatin (the EDP M regimen). This segment is projected to grow at a steady CAGR of approximately 3.3%, supported by its dual role as an adjuvant therapy to prevent recurrence and a primary palliative treatment for metastatic cases. While chemotherapy remains a cornerstone, its growth is slightly tempered by high toxicity profiles, leading to a significant market shift toward the "Fastest Growing" subsegment: Targeted Therapies. These, alongside Radiation Therapy, play vital supporting roles; radiation is increasingly utilized in its advanced forms, such as stereotactic body radiotherapy (SBRT), to manage localized metastases. Meanwhile, Targeted Therapies and Immunotherapies are poised for an explosive CAGR of over 4.7% to 11% through 2034, representing the future of the market as genomic profiling and personalized medicine become standard in late stage oncology care.

Adrenocortical Carcinoma Treatment Market, By End Users

Hospitals

Cancer Treatment Centers

Research Institutes

Based on End Users, the Adrenocortical Carcinoma Treatment Market is segmented into Hospitals, Cancer Treatment Centers, and Research Institutes. At VMR, we observe that Hospitals constitute the dominant subsegment, currently commanding a majority market share of approximately 48% to 52% as of 2026. This dominance is primarily driven by the comprehensive nature of hospitals, which possess the multidisciplinary infrastructure encompassing surgical suites for adrenalectomies, oncology wards, and advanced imaging departments necessary to manage this aggressive and complex malignancy. In North America, the demand is particularly high due to the integration of state of the art diagnostic tools like PET and CT scans within hospital settings, while the Asia Pacific region is experiencing the fastest growth as governments expand their public hospital networks and tertiary care facilities. A defining industry trend within this segment is the digital transformation of patient management through AI driven diagnostic software and electronic health records (EHR), which streamline the coordination between endocrinologists and oncologists.

Cancer Treatment Centers represent the second most dominant subsegment, serving as specialized hubs for advanced systemic therapies. These centers are witnessing significant growth, projected at a CAGR of roughly 6.5%, due to their focused expertise in administering high toxicity regimens such as EDP M and emerging immune checkpoint inhibitors like Nivolumab. Their strength lies in providing a concentrated environment for precision medicine, making them the preferred choice for patients in the EU4 and the UK who require long term maintenance and specialized supportive care. Finally, Research Institutes play a critical supporting role by serving as the primary engines for clinical trial recruitment and molecular research. While their direct revenue contribution is smaller, they are indispensable for the niche adoption of experimental targeted therapies and genomic profiling, holding the potential to redefine future standard of care protocols as more "orphan" drugs transition from the lab to the bedside.

Adrenocortical Carcinoma Treatment Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Based on Distribution Channel, the Adrenocortical Carcinoma Treatment Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. At VMR, we observe that Hospital Pharmacies represent the dominant subsegment, accounting for a commanding market share of approximately 55% to 60% as of 2026. This dominance is primarily driven by the clinical necessity of administering high potency, "specialty only" drugs such as Mitotane and multi agent chemotherapy regimens (EDP M) under strict medical supervision. Because Adrenocortical Carcinoma (ACC) is an ultra rare and aggressive malignancy, treatment protocols are almost exclusively initiated in inpatient settings or specialized oncology wards to manage severe toxicities and hormonal imbalances. North America leads the demand for this channel due to its consolidated health systems and rigorous "Risk Evaluation and Mitigation Strategy" (REMS) programs, while the Asia Pacific region is expanding its hospital pharmacy footprint through massive infrastructure investments in China and Japan. A significant industry trend within this segment is the integration of AI powered pharmacy management systems to monitor therapeutic drug levels in real time, ensuring patient safety and adherence to orphan drug regulations.

Retail Pharmacies serve as the second most dominant subsegment, maintaining a market share of roughly 25% to 30%. Their role is centered on the long term maintenance phase of the patient journey, where survivors require consistent access to oral corticosteroids and mineralocorticoids to manage adrenal insufficiency. Growth in this area is supported by a CAGR of approximately 5.4%, bolstered by the expansion of specialty retail chains that provide high touch patient support and navigation for rare disease medications. Finally, Online Pharmacies represent the fastest growing niche, fueled by the digitalization of healthcare and the increasing consumer demand for home delivery services. While currently holding a smaller revenue contribution, this subsegment is poised for significant future potential as blockchain technology and secure e prescribing tools improve the reliability of global distribution for rare cancer therapies in remote or underserved regions.

Adrenocortical Carcinoma Treatment Market, By Geography

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

As of 2026, the global Adrenocortical Carcinoma (ACC) treatment market is characterized by a strong geographic divide between established Western markets and rapidly modernizing emerging economies. While North America and Europe continue to lead in terms of revenue and clinical trial volume, the Asia Pacific region is emerging as the fastest growing sector due to improving diagnostic capabilities and a massive patient base.

United States Adrenocortical Carcinoma Treatment Market

The United States remains the largest and most influential market for ACC treatment, accounting for nearly 47% of the global market share. This dominance is driven by a highly advanced healthcare ecosystem and the presence of major pharmaceutical innovators. A key growth driver in the U.S. is the robust Orphan Drug Act framework, which provides significant financial incentives for developing treatments for rare diseases like ACC. Current trends show a rapid shift toward targeted therapies and immunotherapies, with several agents receiving FDA "Breakthrough Therapy" designations. Furthermore, the concentration of specialized "Centers of Excellence" (such as MD Anderson and the Mayo Clinic) ensures high treatment compliance and better patient tracking, which solidifies the U.S. as the primary hub for clinical research and high value drug consumption.

Europe Adrenocortical Carcinoma Treatment Market

Europe represents the second largest market, characterized by harmonized regulatory pathways through the European Medicines Agency (EMA). Germany, France, and the UK are the primary contributors, supported by well established rare disease frameworks and national healthcare systems that subsidize high cost orphan drugs. A defining dynamic in Europe is the strong emphasis on multidisciplinary collaborative networks, such as the European Network for the Study of Adrenal Tumors (ENSAT). These networks facilitate cross border clinical trials and standardized treatment protocols (like the EDP M regimen). While the market is mature, growth is currently fueled by the increasing adoption of personalized medicine and genomic profiling, which helps in tailoring specific treatments for aggressive European cohorts.

Asia Pacific Adrenocortical Carcinoma Treatment Market

The Asia Pacific region is the fastest growing market, with China and Japan at the forefront. Growth in this region is propelled by a massive increase in incidentaloma detection where adrenal masses are found during routine health screenings that are increasingly common in urban centers. In China, a compound annual growth rate (CAGR) of over 7% is expected as the government expands its oncology infrastructure and includes more specialty drugs in the National Reimbursement Drug List (NRDL). Trends in this region indicate a rising demand for minimally invasive surgical procedures and a growing domestic biotech sector that is beginning to produce cost effective generic versions of essential drugs like Mitotane, thereby increasing treatment accessibility.

Latin America Adrenocortical Carcinoma Treatment Market

Latin America exhibits a unique market dynamic, particularly in Brazil, which has one of the highest pediatric ACC incidence rates in the world due to a prevalent germline TP53 mutation (the "R337H" variant). This creates a specialized demand for pediatric focused diagnostic and therapeutic tools. While Brazil and Mexico lead the market, regional growth is often hampered by fluctuating economic conditions and a "reimbursement gap" for the most expensive immunotherapies. However, the trend is moving toward international partnerships, where global pharmaceutical firms collaborate with local oncology centers to improve screening and provide "expanded access" programs for late stage patients.

Middle East & Africa Adrenocortical Carcinoma Treatment Market

The Middle East & Africa (MEA) region is an emerging segment, with growth concentrated in the GCC countries (UAE, Saudi Arabia) and South Africa. In the Gulf, massive investments in "Healthcare Cities" and specialized oncology facilities are driving the adoption of Western standard treatment protocols. Current trends show an increasing reliance on medical tourism and a push for localized drug manufacturing to reduce dependence on expensive imports. In contrast, many African nations still face significant restraints related to diagnostic delays; however, the emergence of tele oncology and international aid programs for rare cancers is slowly expanding the reach of basic systemic treatments and surgical interventions in these underserved areas.

Key Players

• The major players in the Adrenocortical Carcinoma Treatment Market are:
• Pfizer Inc.
• Bristol Myers Squibb Company
• Merck Sharp & Dohme Corp.
• Exelixis, Inc.
• Mylan N.V.
• HRA Pharma
• Tempest Therapeutics, Inc.
• Orphagen Pharmaceuticals

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM UP APPROACH
• 2.9 TOP DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET OVERVIEW
• 3.2 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ESTIMATES AND FORECAST (USD MILLION)
• 3.3 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY TYPE OF TREATMENT
• 3.8 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY DISTRIBUTION CHANNEL
• 3.9 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY END USERS
• 3.10 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET, BY TYPE OF TREATMENT (USD MILLION)
• 3.12 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
• 3.13 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET, BY END USERS (USD MILLION)
• 3.14 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET, BY GEOGRAPHY (USD MILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET EVOLUTION
• 4.2 GLOBAL ADRENOCORTICAL CARCINOMA TREATMENT MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE DISTRIBUTION CHANNELS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TYPE OF TREATMENT

• 5.1 OVERVIEW
• 5.2 SURGERY
• 5.3 CHEMOTHERAPY
• 5.4 RADIATION THERAPY
• 5.5 TARGETED THERAPIES

6 MARKET, BY END USERS

• 6.1 OVERVIEW
• 6.2 HOSPITALS
• 6.3 CANCER TREATMENT CENTERS
• 6.4 RESEARCH INSTITUTES

7 MARKET, BY DISTRIBUTION CHANNEL

• 7.1 OVERVIEW
• 7.2 HOSPITAL PHARMACIES
• 7.3 RETAIL PHARMACIES
• 7.4 ONLINE PHARMACIES

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 PFIZER INC.
• 10.2 BRISTOL MYERS SQUIBB COMPANY
• 10.2 MERCK SHARP & DOHME CORP.
• 10.2 EXELIXIS, INC.
• 10.2 MYLAN N.V.
• 10.2 HRA PHARMA
• 10.2 TEMPEST THERAPEUTICS, INC.
• 10.2 ORPHAGEN PHARMACEUTICALS